Measuring cooperative Rev protein-protein interactions on Rev responsive RNA by fluorescence resonance energy transfer

RNA Biology

Volumn 8, Issue 2, 2011, Pages

  Vercruysse, Thomas ^a   Pawar, Sonalika ^b   De Borggraeve, Wim ^b   Pardon, Els ^c   Pavlakis, George N ^d   Pannecouque, Christophe ^a   Steyaert, Jan ^c   Balzarini, Jan ^a   Daelemans, Dirk ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

FRET; HIV 1; Multimerization; Rev; Rev response element; RNA

Indexed keywords

CYAN FLUORESCENT PROTEIN; DNA; REV PROTEIN; RNA; YELLOW FLUORESCENT PROTEIN;

ARTICLE; CONTROLLED STUDY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETIC RECOMBINATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PROTEIN INTERACTION; PROTEIN MULTIMERIZATION; RNA PURIFICATION; RNA SYNTHESIS;

HUMAN IMMUNODEFICIENCY VIRUS 1; LAMA (MAMMAL);

EID: 79954559583     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.4161/hv.8.2.13782     Document Type: Article

References (66)

1. Felber BK, Hadzopoulou-Cladaras M, Cladaras C, Copeland T, Pavlakis GN. rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA. Proc Natl Acad Sci USA 1989; 86:1495-9. (Pubitemid 19078934)
2. Hadzopoulou-Cladaras M, Felber BK, Cladaras C, Athanassopoulos A, Tse A, Pavlakis GN. The rev (trs/art) protein of human immunodeficiency virus type 1 affects viral mRNA and protein expression via a cis-acting sequence in the env region. J Virol 1989; 63:1265-74. (Pubitemid 19061368)
3. Daly TJ, Cook KS, Gray GS, Maione TE, Rusche JR. Specific binding of HIV-1 recombinant Rev protein to the Rev-responsive element in vitro. Nature 1989; 342:816-9. (Pubitemid 20023818)
4. Dayton ET, Powell DM, Dayton AI. Functional analysis of CAR, the target sequence for the Rev protein of HIV-1. Science 1989; 246:1625-9. (Pubitemid 20036702)
5. Malim MH, Bohnlein S, Hauber J, Cullen BR. Functional dissection of the HIV-1 Rev trans-activator - derivation of a trans-dominant repressor of Rev function. Cell 1989; 58:205-14. (Pubitemid 19180092)
6. Fornerod M, Ohno M, Yoshida M, Mattaj IW. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 1997; 90:1051-60. (Pubitemid 27408519)
7. Fukuda M, Asano S, Nakamura T, Adachi M, Yoshida M, Yanagida M, Nishida E. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 1997; 390:308-11. (Pubitemid 27513316)
8. Neville M, Stutz F, Lee L, Davis LI, Rosbash M. The importin-beta family member Crm1p bridges the interaction between Rev and the nuclear pore complex during nuclear export. Curr Biol 1997; 7:767-75. (Pubitemid 27441831)
9. Chang DD, Sharp PA. Regulation by HIV Rev depends upon recognition of splice sites. Cell 1989; 59:789-95. (Pubitemid 20022369)
10. Legrain P, Rosbash M. Some cis- and trans-acting mutants for splicing target pre-mRNA to the cytoplasm. Cell 1989; 57:573-83.
11. Nakielny S, Fischer U, Michael WM, Dreyfuss G. RNA transport. Ann Rev Neurosci 1997; 20:269-301.
12. Blissenbach M, Grewe B, Hoffmann B, Brandt S, Uberla K. Nuclear RNA export and packaging functions of HIV-1 Rev revisited. J Virol 2010; 84:6598-604.
13. Fischer U, Huber J, Boelens WC, Mattaj IW, Luhrmann R. The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell 1995; 82:475-83.
14. Malim MH, Hauber J, Le SY, Maizel JV, Cullen BR. The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 1989; 338:254-7. (Pubitemid 19086926)
15. Perkins A, Cochrane AW, Ruben SM, Rosen CA. Structural and functional characterization of the human immunodeficiency virus rev protein. J Acquir Immune Defic Synd 1989; 2:256-63. (Pubitemid 19147900)
16. Madore SJ, Tiley LS, Malim MH, Cullen BR. Sequence requirements for Rev multimerization in vivo. Virology 1994; 202:186-94. (Pubitemid 24241990)
17. Cole JL, Gehman JD, Shafer JA, Kuo LC. Solution oligomerization of the rev protein of HIV-1: implications for function. Biochemistry 1993; 32:11769-75. (Pubitemid 23344700)
18. Tan R, Chen L, Buettner JA, Hudson D, Frankel AD. RNA recognition by an isolated alpha helix. Cell 1993; 73:1031-40. (Pubitemid 23165617)
19. Daly TJ, Doten RC, Rennert P, Auer M, Jaksche H, Donner A, et al. Biochemical characterization of binding of multiple HIV-1 Rev monomeric proteins to the Rev responsive element. Biochemistry 1993; 32:10497-505. (Pubitemid 23320176)
20. Daugherty MD, D'Orso I, Frankel AD. A solution to limited genomic capacity: using adaptable binding surfaces to assemble the functional HIV Rev oligomer on RNA. Mol Cell 2008; 31:824-34.
21. Kjems J, Frankel AD, Sharp PA. Specific regulation of mRNA splicing in vitro by a peptide from HIV-1 Rev. Cell 1991; 67:169-78 (Pubitemid 121001433)
22. Mann DA, Mikaelian I, Zemmel RW, Green SM, Lowe AD, Kimura T, et al. A molecular rheostat. Co-operative rev binding to stem I of the rev-response element modulates human immunodeficiency virus type-1 late gene expression. J Mol Biol 1994; 241:193-207.
23. Malim MH, Cullen BR. HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: implications for HIV-1 latency. Cell 1991; 65:241-8. (Pubitemid 121006055)
24. Pomerantz RJ, Seshamma T, Trono D. Efficient replication of human immunodeficiency virus type 1 requires a threshold level of Rev: potential implications for latency. J Virol 1992; 66:1809-13.
25. Pomerantz RJ, Trono D, Feinberg MB, Baltimore D. Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency. Cell 1990; 61:1271-6.
26. Thomas JR, Hergenrother PJ. Targeting RNA with Chem Rev 2008; 108:1171-224.
27. Chaloin L, Smagulova F, Hariton-Gazal E, Briant L, Loyter A, Devaux C. Potent inhibition of HIV-1 replication by backbone cyclic peptides bearing the Rev arginine rich motif. J Biomed Sci 2007; 14:565-84. (Pubitemid 47414768)
28. Hariton-Gazal E, Rosenbluh J, Zakai N, Fridkin G, Brack-Werner R, Wolff H, et al. Functional analysis of backbone cyclic peptides bearing the arm domain of the HIV-1 Rev protein: characterization of the karyophilic properties and inhibition of Rev-induced gene expression. Biochemistry 2005; 44:11555-66. (Pubitemid 41209091)
29. Mills NL, Daugherty MD, Frankel AD, Guy RK. An alpha-helical peptidomimetic inhibitor of the HIV-1 Rev-RRE interaction. J Am Chem Soc 2006; 128:3496-7.
30. Moehle K, Athanassiou Z, Patora K, Davidson A, Varani G, Robinson JA. Design of beta-hairpin peptidomimetics that inhibit binding of alpha-helical HIV-1 Rev protein to the rev response element RNA. Angewandte Chemie (International ed) 2007; 46:9101-4. (Pubitemid 350232777)
31. Chin DJ. Inhibition of human immunodeficiency virus type 1 Rev-Rev-response element complex formation by complementary oligonucleotides. J Virol 1992; 66:600-7.
32. Moses AC, Huang SW, Schepartz A. Inhibition of Rev. RRE complexation by triplex tethered oligonucleotide probes. Bioorg Med Chem 1997; 5:1123-9.
33. Prater CE, Saleh AD, Wear MP, Miller PS. Chimeric RNase H-competent oligonucleotides directed to the HIV-1 Rev response element. Bioorg Med Chem 2007; 15:5386-95. (Pubitemid 46963004)
34. Fineberg K, Fineberg T, Graessmann A, Luedtke NW, Tor Y, Lixin R, et al. Inhibition of nuclear import mediated by the Rev-arginine rich motif by RNA molecules. Biochemistry 2003; 42:2625-33.
35. Lee SW, Gallardo HF, Gilboa E, Smith C. Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain. J Virol 1994; 68:8254-64. (Pubitemid 24362717)
36. Lisziewicz J, Zeng G, Gratas C, Weinstein JN, Lori F. Combination gene therapy: synergistic inhibition of human immunodeficiency virus Tat and Rev functions by a single RNA molecule. Hum Gene Ther 2000; 11:807-15. (Pubitemid 30202472)
37. Michienzi A, De Angelis FG, Bozzoni I, Rossi JJ. A nucleolar localizing Rev binding element inhibits HIV replication. AIDS Res Ther 2006; 3:13.
38. Roisin A, Robin JP, Dereuddre-Bosquet N, Vitte AL, Dormont D, Clayette P, Jalinot P. Inhibition of HIV-1 replication by cell-penetrating peptides binding Rev. J Biol Chem 2004; 279:9208-14. (Pubitemid 38295984)
39. Daelemans D, Afonina E, Nilsson J, Werner G, Kjems J, De Clercq E, et al. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci USA 2002; 99:14440-5. (Pubitemid 35257690)
40. Wolff B, Sanglier JJ, Wang Y. Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem Biol 1997; 4:139-47. (Pubitemid 27161752)
41. Van Neck T, Pannecouque C, Vanstreels E, Stevens M, Dehaen W, Daelemans D. Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action. Bioorg Med Chem 2008; 16:9487-97.
42. Vercruysse T, Pardon E, Vanstreels E, Steyaert J, Daelemans D. An intrabody based on a llama singledomain antibody targeting the N-terminal alphahelical multimerization domain of HIV-1 rev prevents viral production. J Biol Chem 2010; 285:21768-80.
43. Edgcomb SP, Aschrafi A, Kompfner E, Williamson JR, Gerace L, Hennig M. Protein structure and oligomerization are important for the formation of exportcompetent HIV-1 Rev-RRE complexes. Protein Sci 2008; 17:420-30. (Pubitemid 351281542)
44. Thomas SL, Oft M, Jaksche H, Casari G, Heger P, Dobrovnik M, et al. Functional analysis of the human immunodeficiency virus type 1 Rev protein oligomerization interface. J Virol 1998; 72:2935-44. (Pubitemid 28175531)
45. Jain C, Belasco JG. Structural model for the cooperative assembly of HIV-1 Rev multimers on the RRE as deduced from analysis of assembly-defective mutants. Mol Cell 2001; 7:603-14. (Pubitemid 32706352)
46. Dimattia MA, Watts NR, Stahl SJ, Rader C, Wingfield PT, Stuart DI, et al. Implications of the HIV-1 Rev dimer structure at 3.2 A resolution for multimeric binding to the Rev response element. Proc Natl Acad Sci USA 2010; 107:5810-4.
47. Berney C, Danuser G. FRET or no FRET: a quantitative comparison. Biophys J 2003; 84:3992-4010. (Pubitemid 36637892)
48. Chen H, Puhl HL, 3rd, Koushik SV, Vogel SS, Ikeda SR. Measurement of FRET efficiency and ratio of donor to acceptor concentration in living cells. Biophys J 2006; 91:39-41.
49. Zhou D, Piper JD, Abell C, Klenerman D, Kang DJ, Ying L. Fluorescence resonance energy transfer between a quantum dot donor and a dye acceptor attached to DNA. Chem Commun (Camb) 2005; 4807-9. (Pubitemid 41503195)
50. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature 1993; 363:446-8. (Pubitemid 23179389)
51. Muyldermans S, Cambillau C, Wyns L. Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains. Trends Biochem Sci 2001; 26:230-5. (Pubitemid 32289241)
52. Pond SJ, Ridgeway WK, Robertson R, Wang J, Millar DP. HIV-1 Rev protein assembles on viral RNA one molecule at a time. Proc Natl Acad Sci USA 2009; 106:1404-8.
53. Brice PC, Kelley AC, Butler PJ. Sensitive in vitro analysis of HIV-1 Rev multimerization. Nucleic Acids Res 1999; 27:2080-5. (Pubitemid 29219235)
54. Malim MH, Tiley LS, McCarn DF, Rusche JR, Hauber J, Cullen BR. HIV-1 structural gene expression requires binding of the Rev trans-activator to its RNA target sequence. Cell 1990; 60:675-83.
55. Olsen HS, Cochrane AW, Dillon PJ, Nalin CM, Rosen CA. Interaction of the human immunodeficiency virus type 1 Rev protein with a structured region in env mRNA is dependent on multimer formation mediated through a basic stretch of amino acids. Genes Dev 1990; 4:1357-64.
56. Zapp ML, Hope TJ, Parslow TG, Green MR. Oligomerization and RNA binding domains of the type 1 human immunodeficiency virus Rev protein: a dual function for an arginine-rich binding motif. Proc Natl Acad Sci USA 1991; 88:7734-8. (Pubitemid 21915229)
57. Zhang CY, Johnson LW. Quantum-dot-based nanosensor for RRE IIB RNA-Rev peptide interaction assay. J Am Chem Soc 2006; 128:5324-5.
58. Luedtke NW, Tor Y. Fluorescence-based methods for evaluating the RNA affinity and specificity of HIV-1 Rev-RRE inhibitors. Biopolymers 2003; 70:103-19.
59. Daelemans D, Costes SV, Cho EH, Erwin-Cohen RA, Lockett S, Pavlakis GN. In vivo HIV-1 Rev multimerization in the nucleolus and cytoplasm identified by fluorescence resonance energy transfer. J Biol Chem 2004; 279:50167-75.
60. Daelemans D, Costes SV, Lockett S, Pavlakis GN. Kinetic and molecular analysis of nuclear export factor CRM1 association with its cargo in vivo. Mol Cell Biol 2005; 25:728-39. (Pubitemid 40096593)
61. Wingfield PT, Stahl SJ, Payton MA, Venkatesan S, Misra M, Steven AC. HIV-1 Rev expressed in recombinant Escherichia coli: purification, polymerization and conformational properties. Biochemistry 1991; 30:7527-34.
62. Heaphy S, Finch JT, Gait MJ, Karn J, Singh M. Human immunodeficiency virus type 1 regulator of virion expression, rev, forms nucleoprotein filaments after binding to a purine-rich "bubble" located within the rev-responsive region of viral mRNAs. Proc Natl Acad Sci USA 1991; 88:7366-70.
63. Watts NR, Misra M, Wingfield PT, Stahl SJ, Cheng N, Trus BL, et al. Three-dimensional structure of HIV-1 Rev protein filaments. J Struct Biol 1998; 121:41-52. (Pubitemid 28363251)
64. Auer M, Gremlich HU, Seifert JM, Daly TJ, Parslow TG, Casari G, Gstach H. Helix-loop-helix motif in HIV-1 Rev. Biochemistry 1994; 33:2988-96. (Pubitemid 24103360)
65. Blanco FJ, Hess S, Pannell LK, Rizzo NW, Tycko R. Solid-state NMR data support a helix-loop-helix structural model for the N-terminal half of HIV-1 Rev in fibrillar form. J Mol Biol 2001; 313:845-59. (Pubitemid 33063431)
66. Daelemans D, Vandamme AM, De Clercq E. Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy. Antivir Chem Chemother 1999; 10: 1-14. (Pubitemid 29110119)